Genedrive Plc (GDR) 2012年年度报告「LSE」.pdf

1、DiversityInnovation Progress GrowthEpistem Holdings Plc Annual Report 2012I am pleased to report major progress in a number of the Companys core development programmes and the acceleration of investment in our first diagnostic product in the results for the year ended 30 June 2012.I am also pleased

2、to report the recent completion of the first high value commercial contract for our Genedrive platform with Becton Dickinson.This agreement coupled with the earlier reported Xcelris Laboratories agreement signals the beginning of a new and exciting phase of revenue growth for Epistem and its investo

3、rs.David Evans Non-executive Chairman 1StrengthTotal sales of 5.6m driven by a solid performance by Contract Research Services with strong and emerging growth in our Personalised Medicine division.2TechnologyHigh investment in our leading technologies to accelerate their advancement over the reporti

4、ng period with particular emphasis on the Genedrive platform and continued investment in Novel Therapies lead discovery programme.3FinancialA placing of shares during the period underpinned a financial strengthening of the Company with increased cash reserves.4InvestorClear investor communication of

5、 the Companys strategy and performance remains a key element of our success.Company OverviewHighlightsTotal sales of 5.6m driven by a solid performance by Contract Research Services and strong growth in our Personalised Medicine division.More than 100%year on year growth in the Personalised Medicine

6、 division revenues on back of collaborations with GSK,Sanofi-Aventis and emerging Genedrive sales.EU registration and preparations for launch of first major molecular diagnostic product(Genedrive).Recent announcement of major international distribution agreement with Becton Dickinson in Tuberculosis